A gut feeling for microbes and a small amount of venture cash could help a San Francisco startup unleash a new, faster way to identify diseases and uncover personalized treatments.
Second Genome Inc., whose founders include serial biotech entrepreneur Corey Goodman and two of Lawrence Berkeley National Laboratory scientists, said Tuesday morning that it received $5 million in a Series A round co-led by new investors Advanced Technology Ventures and Morgenthaler Ventures.
No comments:
Post a Comment